타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | LBCL, FL |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. |
Positioning Development positioning | 2L+ |
Technology Vector | Retrovirus |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CRS, ICANS, cytopenias |
Toxicology CRS | Grade ≥3 ~13% |
Clinical Safety signal | CRS, ICANS, cytopenias |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) |
Overview Company | Kite / Gilead |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | LBCL, FL |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Rapid manufacturing, CD28 signaling |
Positioning Known limitation | CD19 antigen loss, T-cell exhaustion, and hostile tumor microenvironment. |
Positioning Development positioning | 2L+ |
Technology Vector | Retrovirus |
MoA Mechanism | Autologous T cells transduced with a retroviral vector encoding an anti-CD19 CAR (scFv + CD28 + CD3ζ). CAR T cells expand in vivo, recognize CD19 on B cells, and mediate cytotoxic killing. |
MoA Biomarker | CD19 expression on lymphoma cells; CAR T expansion in blood. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | CRS, ICANS, cytopenias |
Toxicology CRS | Grade ≥3 ~13% |
Clinical Safety signal | CRS, ICANS, cytopenias |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교